Background: Hyperhomocysteinemia is a cardiovascular disease (CVD) risk factor. We determined plasma homocysteine (Hcy) reference values at optimized vitamin status and investigated their influence on the prevalence of hyperhomocysteinemia in healthy adults. Results were compared with those obtained using European Concerted Action Project (ECAP) cutoff values. Methods: Healthy adults (n ‫؍‬ 101) received folic acid (5 mg/day) and vitamin B 12 (1 mg/day) for 2 weeks and the same dosages of folic acid and vitamin B 12 plus vitamin B 6 (1 mg ⅐ kg ؊1 ⅐ day ؊1 ) during the following 2 weeks. Hcy concentrations, both fasting and 6-h post-methionine load, were determined at baseline and after 4 weeks. Results: Baseline (4 weeks) fasting and 6-h postload Hcy reference values were 4.7-14.6 (4.1-9.3) and 18.8 -49.7 (12.9 -35.1) mol/L, respectively. Mean fasting and 6-h postload Hcy decreased after 4 weeks of vitamin supplementation by 3.5 mol/L (33.5%) and 8.5 mol/L (26.3%), respectively. The percentages of subjects exhibiting significant decreases in fasting Hcy following vitamin supplementation were 88% (all subjects), 92% (non-vitamin users), and 72% (vitamin users). The prevalences of hyperhomocysteinemia with use of ECAP cutoff values were 29% for all groups, 29% for men, 27% for premenopausal women, and 53% for postmenopausal women. With vitamin-optimized cutoff values, prevalences were 58%, 58%, 76%, and 89%,
© 2001 American Association for Clinical Chemistry
Hyperhomocysteinemia is a cardiovascular disease (CVD) 3 risk factor. High plasma homocysteine (Hcy) is also associated with neural tube defects, thrombosis, pregnancy complications, mental disorders, and possibly cancer (1, 2 ) . Hyperhomocysteinemia is defined as an increased fasting plasma Hcy (fasting Hcy), an increased plasma Hcy 6 h after a methionine loading test (MLT; 6-h postload Hcy), or both. To date, there is no general agreement on hyperhomocysteinemia cutoff values. These values derive ideally from the relationship between plasma Hcy and absolute CVD risk, and represent those fasting and 6-h postload Hcy concentrations at which the absolute CVD risk becomes unacceptable by consensus. On the basis of the gradually increasing relative CVD risk in a multicenter case-control study, the European Concerted Action Project (ECAP) defined cutoff values of 12.1 mol/L for a fasting Hcy and 38.0 mol/L for a 6-h postload Hcy (1, 3 ) . The Nutrition Committee of the American Heart Association proposed Ͻ10 mol/L as a reasonable fasting Hcy diagnostic cutoff value and treat-ment goal for subjects at increased risk of CVD (4 ) , based on four studies on the relationship between Hcy and relative CVD risk. The widespread use of such cutoff values, notably for primary prevention, awaits the outcome of randomized prospective studies showing that decreasing Hcy actually decreases CVD risk (5 ) . Studies on the effects of Hcy-lowering therapy have already indicated its favorable effects on cardiovascular morbidity in patients with severe hyperhomocysteinemia caused by cystathionine-␤-synthase deficiency, and possibly on the development of new cardiovascular events in patients with premature atherosclerosis and mild hyperhomocysteinemia (6, 7 ) . Anticipating that the randomized prospective studies confirm that decreasing Hcy reduces CVD risk, it may be argued that optimal plasma Hcy concentrations correspond with the lowest achievable concentrations because it has become clear that, as with cholesterol, CVD risk increases gradually with increasing plasma Hcy without a clear threshold (8 ) .
Plasma Hcy concentrations depend on genetic, environmental, and other factors, such as kidney function (1 ) . Some vitamins are cofactors or cosubstrates in the metabolic clearance of Hcy (1 ) , and it has repeatedly been demonstrated for populations in many countries that both fasting and 6-h postload plasma Hcy concentrations decrease with administration of vitamin B 12 , vitamin B 6 , and particularly folic acid in both healthy subjects and patients with CVD (9 -11 ) . Reaching optimal status for these vitamins in terms of their influence on plasma Hcy may, therefore, constitutes the easiest and least expensive way to decrease plasma Hcy concentrations and thereby possibly reduce CVD risk. From the clinical chemical point of view, such an approach would require the use of Hcy reference values at optimized vitamin status, as suggested previously by Ubbink et al. (12 ) .
We determined fasting and 6-h postload Hcy reference values at optimized folate, vitamin B 12 , and vitamin B 6 status (hereafter referred to as "vitamin-optimized Hcy reference values") and investigated their influence on the prevalence of hyperhomocysteinemia in 101 healthy Dutch adults. The outcome was compared with the prevalence calculated from the use of ECAP cutoff values. In contrast to our previous study (13 ) , we also determined 6-h postload Hcy reference values, coadministered vitamin B 12 , and supplemented the three vitamins for a longer time period.
Subjects and Methods study group
Apparently healthy subjects (ages Ն18 years) were recruited from hospital employees and from students of the Pharmacy and Medicine Departments of the Groningen University Hospital. Subjects Ͼ50 years were recruited from sport and community center visitors. Exclusion criteria were pregnancy, psoriasis, epilepsy, kidney insufficiency, increased serum liver enzymes, CVD, and use of drugs that interfere with folic acid, vitamin B 12 , or vitamin B 6 metabolism. The study protocol was approved by the medical ethics committee of the Groningen University Hospital and was in agreement with local ethics standards and the Helsinki Declaration of 1975, as revised in 1996.
study design
Indices of kidney and liver pathology and hematological abnormalities were investigated at baseline by measurement of serum creatinine, aspartate aminotransferase, alanine aminotransferase, ␥-glutamyltranspeptidase, and alkaline phosphatase, and standard hematological indices (erythrocytes, leukocytes, platelets, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration). Anthropometric data, menopausal status, and supplemental vitamin intake were assessed by questionnaire. The total study duration was 4 weeks. The volunteers took folic acid and vitamin B 12 during the first 2 weeks, and folic acid, vitamin B 12 , and vitamin B 6 during the following 2 weeks. The dosages were 5 mg/day for folic acid [12. 5 times the Recommended Dietary Allowance (RDA)], 1 mg/day for vitamin B 12 (417 times the RDA) and 1 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 for vitamin B 6 (46 -60 times the RDA; maximum, 100 mg/day). The participants were asked to take the supplements at breakfast and to consume protein-poor meals on the day before sampling (i.e., at baseline and after 4 weeks). No supplements were taken on the sampling days. Blood was collected in the fasting state (Ͼ10 h fasting) at baseline and after 4 weeks for the analyses of plasma Hcy (fasting Hcy), serum folate, serum vitamin B 12 , and whole-blood vitamin B 6 . MLTs were performed at baseline and after 4 weeks by administration of 0.1 g of methionine per kg of body weight, suspended in orange juice. Blood samples were taken 6 h after methionine ingestion for the analysis of plasma Hcy (6-h postload Hcy). The participants were instructed to consume only protein-poor food during the test.
analytical methods
Blood and EDTA-blood were collected. EDTA-blood was immediately placed in melting ice. Both samples were processed within 1 h to serum and EDTA-plasma. Serum folate and vitamin B 12 were determined by an immunofluorometric method (Autodelfia; Wallac Oy). Wholeblood vitamin B 6 was determined by HPLC (14 ) . Plasma Hcy was determined by an immunochemical method (IMx; Abbott Laboratories). This method measures plasma total Hcy, which is the sum of both reduced and oxidized forms in the circulation. Standard hematological indices were determined with a Coulter STKS (Coulter Corporation). Serum creatinine, aspartate aminotransferase, alanine aminotransferase, ␥-glutamyltranspeptidase, and alkaline phosphatase were determined with a MEGA (Merck).
data evaluation and statistics
Data were evaluated on the basis of intention to treat and were processed with Microsoft Excel. Reference intervals for fasting and 6-h postload Hcy concentrations were calculated according to methods recommended by the IFCC (15 ) by taking the central 95% interval of the data. Vitamin-optimized cutoff values for the establishment of hyperhomocysteinemia were calculated for the total group, for men, and for pre-and postmenopausal women separately. Cutoff values were placed at the 97.5th percentiles. ECAP cutoff values for fasting and 6-h postload Hcy were 12.1 and 38.0 mol/L (total group), 11.9 and 39.8 mol/L (men Ͻ45 years), 12.6 and 38.0 mol/L (men Ն45 years), 10.4 and 34.1 mol/L (women Ͻ45 years), and 11.4 and 36.9 mol/L (women Ն45 years), respectively (1 ).
Statistical analyses were performed with Microsoft SPSS 9.0. Associations were analyzed by Spearman rank tests, longitudinal changes in vitamin and Hcy concentrations by the paired Student t-test (gaussian distributions) or by Wilcoxon signed-ranks tests (nonparametric distributions). P Ͻ0.05 was considered significant.
Individual fasting Hcy decreases were considered significant when individual percentile changes exceeded 2.77 ϫ CV anal,biol (i.e., significantly higher change than the combined intraassay analytical and mean intraindividual biological variations). On the basis of a mean CV biol of 7.03% (16 ) and a CV anal of 1.85% (our observations), the CV anal,biol was estimated to be 7.27%. The least significant change in plasma Hcy was therefore calculated to be 20.1%. Because there are no reliable data on the biological variation of a 6-h postload Hcy, the least significant 6-h postload Hcy change could not be determined.
Results

study group
A total of 102 apparently healthy subjects were recruited. One of the subjects was excluded because of a high serum creatinine. Data for 101 participants (age range, 18 -76 years) were used for the determination of fasting Hcy reference values at baseline. Reference values for the 6-h postload Hcy were determined from data for 100 participants because the 6-h postload Hcy value of 1 subject was missing. Of the 101 subjects, 1 (1%) had folate concentrations below our locally used reference values (8 - Table 1 . Before supplementation, men and premenopausal women had different fasting Hcy (P Ͻ0.05). Men and pre-and postmenopausal women differed in fasting Hcy after supplementation (P Ͻ0.001) and in 6-h postload Hcy both before (P Ͻ0.01) and after (P Ͻ0.0001) supplementation. Fasting Hcy was independent of age in men and women before supplementation, but was age dependent after supplementation in men (r ϭ 0.484; P ϭ 0.001) and all women combined (r ϭ 0.345; P ϭ 0.016). The 6-h postload Hcy was age dependent in all women combined, both before (r ϭ 0.399; P ϭ 0.003) and after (r ϭ 0.433; P ϭ 0.002) supplementation.
During the supplementation period, circulating vitamin concentrations increased, whereas fasting and 6-h postload Hcy concentrations decreased in the total study group and in each of the three subgroups. The mean (Ϯ SD) decreases in fasting Hcy and 6-h postload Hcy during the study were 3.5 Ϯ 2.1 mol/L (33.5% Ϯ 13.5%) and 8.5 Ϯ 5.9 mol/L (26.3% Ϯ 14.7%), respectively, for the total study group. The percentage of subjects with significantly decreased fasting Hcy after vitamin supplementation was 88%. Forty-five percent (5 of 11) of the subjects who did not exhibit a Hcy decrease used vitamin supplements at baseline. The percentage of vitamin supplement users in the group that did exhibit a Hcy decrease was 16% (13 of 82). Hcy decreased significantly in 92% (69 of 75) of the participants who did not use vitamin supplements at baseline and in 72% (13 of 18) of the subjects who did use vitamin supplements at baseline. It should be noted that supplemental vitamin intake was highly variable but generally low. Reference values for baseline fasting and 6-h postload Hcy were 4.7-14.6 and 18.8 -49.7 mol/L, respectively, for the total study group. Vitamin-optimized fasting and 6-h postload Hcy reference values were 4.1-9.3 and 12.9 -35.1 mol/L, respectively.
hyperhomocysteinemia prevalence at different Hcy cutoff values
The consequences of the use of different Hcy cutoff values for the diagnosis of hyperhomocysteinemia are depicted in Table 2 and Fig. 1 . When we applied the whole group and subgroup-specific vitamin-optimized cutoff values (Table 1) for evaluation of fasting and 6-h postload Hcy at baseline, 58% of the total group, 58% of the men, 76% of the premenopausal women, and 89% of the postmenopausal women had increased values. With ECAP cutoff values, these percentages were 29% for the total group, 29% for the men, 27% for the premenopausal women, and 53% for the postmenopausal women.
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The use of ECAP or vitamin-optimized cutoffs had different impacts for a fasting Hcy and 6-h postload Hcy on the diagnosis of hyperhomocysteinemia ( Table 2 ). The use of vitamin-optimized reference values produced a sharp decrease in the percentage of subjects who could be diagnosed as hyperhomocysteinemic only on the basis of a 6-h postload Hcy. The percentages decreased from 14% to 2% for the total group, from 8% to 2% for men, from 3% to 0% for premenopausal women, and from 42% to 5% for postmenopausal women. On the other hand, the use of vitamin-optimized reference values increased the percentages of subjects who could be diagnosed only on the basis of a fasting Hcy. The percentages increased from 10% to 29% for the total group, from 17% to 29% for men, from 15% to 55% for premenopausal women, and from 0% to 63% for postmenopausal women.
Discussion
We investigated the influence of the use of vitaminoptimized plasma Hcy cutoff values on the prevalence of hyperhomocysteinemia in 101 healthy Dutch adults. The outcome was compared with the hyperhomocysteinemia prevalence calculated from the use of ECAP cutoff values. The ECAP is, to our knowledge, the only study to consider a 6-h postload Hcy, and we are the first to use a vitamin-optimized 6-h postload Hcy. Other studies have also determined vitamin-optimized fasting Hcy reference values (12, 13, 17, 18 ) . The outcomes (as reference values) were 5.6 -20.4 mol/L (13 ), 4.9 -11.7 mol/L (12 ), 4.4 -10.9 mol/L (17 ), and 5.5-11.5 mol/L (as range) (18 ) compared with the present values of 4.1-9.3 mol/L. The higher vitamin-optimized values found in our previous study (13 ) were likely to be caused by the short (1 week) supplementation period of vitamin B 6 and folic acid and the high number of subjects with low vitamin B 12 status at the end of the study. The present values are similar to those reported by Ubbink et al. (12 ) and Rasmussen et al. (17 ) , with differences, if any, probably deriving from extrapolating effects and gender differences, for the study by Ubbink et al. (12 ) , or the higher mean age and lack of vitamin B 6 cosupplementation in the study by Rasmussen et al. (17 ) . Different vitamin B 2 (riboflavin) status may also explain disparities (19 ) .
Vitamin-optimized Hcy reference values are independent from the background intake of vitamins via the diet or supplements, which is probably at the base of the encountered international similarities. Until the beneficial effect of decreasing Hcy on CVD risk is confirmed, one may use these upper limits of the reference intervals as cutoff values for both the diagnosis and treatment of hyperhomocysteinemia because treatment consists of supplementation with folic acid, vitamin B 12 , and vitamin B 6 . The use of the upper limit of the vitamin-optimized fasting Hcy reference interval (i.e., 9.3 mol/L) is in line with the Ͻ10 mol/L recommendation of the American (88) 37 (82) 29 (97) 16 (89) 6h-Hcy, Heart Association for subjects with increased CVD risk and makes the presence of (sub)clinical deficiencies of the three B vitamins unlikely. We used relatively high, nontoxic vitamin dosages to obtain new, vitamin-optimized, plasma Hcy steady-state values by rapid means. The metaanalysis of the Homocysteine Lowering Trialists' Collaboration (9 ) and the study of Lobo et al. (10 ) indicated that a daily folic acid dose of 400 -500 g in combination with vitamin B 12 and vitamin B 6 is equally effective compared with folic acid dosages up to 5 mg/day. These studies indicate that lower vitamin dosages would have led to similar results and that there is no support for any concern that pharmacological dosages produce nonphysiologically low Hcy values.
Compared with ECAP cutoff values, the use of vitamin-optimized cutoff values increased the diagnostic value of a fasting Hcy and decreased the diagnostic value of a 6-h postload Hcy for the establishment of hyperhomocysteinemia ( Table 2 ). The remaining very low prevalence of an isolated abnormal 6-h postload Hcy does not seem to justify the use of a MLT when vitamin-optimized cutoff values are used. It should also be noted that a MLT is not necessarily harmless (20, 21 ) .
Twenty-nine percent of our healthy volunteers had hyperhomocysteinemia according to the ECAP cutoff values, which is in excellent agreement with the 30% of controls with hyperhomocysteinemia in the ECAP study (3 ) . The hyperhomocysteinemia prevalence increased to 58% with use of vitamin-optimized cutoff values. When we considered men and pre-and postmenopausal women separately, the prevalences were 29%, 27%, and 53%, based on the ECAP cutoffs, and 58%, 76%, and 89%, based on vitamin-optimized cutoff values, respectively. These pretest probabilities may underscore the situation when the goal is to reach the lowest Hcy concentrations because Table 2 .
at least 88% of the subjects had significantly decreased fasting Hcy after folic acid, vitamin B 12 , and vitamin B 6 supplementation. The probability was even higher (92%) for subjects who did not take vitamin supplements. These high pretest probabilities preclude any meaningful role for the ordering of a Hcy test in the general population because this would require a pretest probability in the 25-65% range, according to the rules of "evidence based laboratory medicine" (22 ) . Decreasing Hcy by the use of vitamin supplements is advised for hyperhomocysteinemic CVD patients and patients at high CVD risk because of its expected beneficial effect (1, 4 ) . In view of the lack of evidence that decreasing Hcy decreases CVD risk, there is at present no indication for ordering a Hcy test for CVD prevention in the general population. Any future confirmation of a beneficial effect of decreasing Hcy on CVD risk could, from the public health point of view, be translated into adjustment of RDAs, improvement of B-vitamin status through food fortification, and concomitant implementation of vitamin-optimized reference values. Fortification of grain products in the United States with 140 g of folic acid/100 g has changed the mean fasting plasma Hcy from 10.1 to 9.4 mol/L in non-B-vitamin users and from 7.9 to 8.5 mol/L in B-vitamin users (23 ) . It concomitantly changed the percentage of subjects with plasma Hcy above the 9.3 mol/L vitamin-optimized cutoff value from ϳ63% to 52% (non-B-vitamin users) and from 33% to 37% (B-vitamin users). These data show, from a clinical chemical point of view, that the present fortification dosage, or the choice of fortified food products (24 ) , in the United States is inadequate to prevent a large increase of the number of Hcy tests from the moment that a causal relationship between hyperhomocysteinemia and CVD is established. An explosion of Hcy test requests can be avoided only when the daily supplemental B-vitamin intake of the general population reduces the probability to Ͻ25% that a random healthy subject has a fasting Hcy Ͼ9.3 mol/L. It seems that Hcy testing at a pretest probability of Ͻ25% in the general population will be restricted to risk assessment of CVD patients and relatives with high CVD risk, to diagnosis of inborn errors in methionine and vitamin B 12 metabolism, and to assessment of vitamin status in subjects at risk or suspected of low vitamin status (e.g., malabsorption syndrome, poor diet, and certain drugs) (4 ).
In conclusion, there is remarkable uniformity in vitaminoptimized fasting Hcy reference values among different authors. Use of vitamin-optimized cutoff values increases the diagnostic value of a fasting Hcy and decreases the diagnostic value of a 6-h postload Hcy when compared with the use of ECAP cutoff values. With vitamin-optimized reference values, there does not seem to be a remaining role for the MLT. Current use of vitaminoptimized cutoff values offers no indications for ordering of a Hcy test: the pretest probability for the diagnosis hyperhomocysteinemia amounts to 58 -89%, depending on gender and menopausal status, and the pretest probability of a Hcy decrease after supplementation with folic acid, vitamin B 12 , and vitamin B 6 is 88% in apparently healthy subjects. Demonstration of a beneficial effect of decreasing Hcy on CVD risk would justify augmentation of the population's B-vitamin status and the concomitant implementation of vitamin-optimized Hcy cutoff values. Proper augmentation of vitamin B status would drastically lower the prevalence of hyperhomocysteinemia, with remaining indications for a Hcy test for CVD patients and relatives with high CVD risk, and the diagnosis of certain inborn errors and subjects suspected or at risk of low B-vitamin status.
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